SEATTLE--(BUSINESS WIRE)--MitoPharm Corporation, Inc. (Pinksheets:MTPM), announced today that it has entered into an exclusive, worldwide licensing agreement with Hong Kong University of Science and Technology for the use and commercialization of its new, patent pending process for the extraction of "(-) Schisandrin B” and “Schisandrin B.” The terms of the agreement were not disclosed.
